Avedro Inc (AVDR1)

Sector:
HEALTH CARE
Industry:
HEALTH CARE SUPPLIES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Reza Zadno
Employees:
201 JONES ROAD, WALTHAM, MA 02451
781 768 3400

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Avedro, Inc., an ophthalmic pharmaceutical and medical device company, develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness. The company's Avedro Corneal Remodeling platform comprises KXL and Mosaic systems, which deliver ultraviolet A or UVA light, and a suite of single-use riboflavin drug formulations. Its Avedro Corneal Remodeling platform treats corneal ectatic disorders and corrects refractive conditions; and KXL system in combination with Photrexa drug formulations used for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Avedro sells its products primarily to ophthalmologists, hospitals, and ambulatory surgery centers through a direct sales force in the United States, as well as through medical device distributors internationally. The company was formerly known as ThermalVision, Inc. and changed its name to Avedro, Inc. in October 2005. Avedro, Inc. was incorporated in 2002 and is headquartered in Waltham, Massachusetts.

Data derived from most recent annual or quarterly report
Market Cap 394.049 Million Shares Outstanding17.14 Million Avg 30-day Volume 92.044 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.52
Price to Revenue0.0 Debt to Equity0.9294 EBITDA0
Price to Book Value9.0197 Operating Margin0.0 Enterprise Value732.13 Million
Current Ratio16.817 EPS Growth0 Quick Ratio15.013
1 Yr BETA 1.7175 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth0.0 Altman Z-Score17.6759 Free Cash Flow to Firm 0
View SEC Filings from AVDR1 instead.

View recent insider trading info

Funds Holding AVDR1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AVDR1

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2019-11-21:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-11-18:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-11-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-08-07:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.02: Results of Operations and Financial Condition
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-11-08:
    Item 8.01: Other Events
  • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    PALMISANO ROBERT J

    • Director
    No longer subject to file 2019-11-21 0

    SILVERSTEIN JONATHAN

    • Director
    • 10% Owner
    No longer subject to file 2019-11-21 0

    INTERWEST PARTNERS X LP

    INTERWEST MANAGEMENT PARTNERS X, LLC

    ORONSKY ARNOLD L

    NASR KHALED

    DESAI KEVAL

    KLIMAN GILBERT H

    • 10% Owner
    No longer subject to file 2019-11-21 0

    ZURBAY DONALD

    • Director
    No longer subject to file 2019-11-21 0

    SCHUERMANN JAMES CHIEF BUSINESS OFFICER

    • Officer
    No longer subject to file 2019-11-21 0

    KONG GARHENG

    • Director
    No longer subject to file 2019-11-21 0

    BAVIER PAUL S GENERAL COUNSEL AND SEC.

    • Officer
    No longer subject to file 2019-11-21 0

    GRIFFIN THOMAS E CHIEF FINANCIAL OFFICER

    • Officer
    No longer subject to file 2019-11-21 0

    ZADNO REZA PRESIDENT AND CEO

    • Officer
    • Director
    No longer subject to file 2019-11-21 0

    FIRST DAVID CHIEF HUMAN RESOURCES OFFICER

    • Officer
    No longer subject to file 2019-11-21 0

    RAJPAL RAJESH K. CHIEF MEDICAL OFFICER

    • Officer
    No longer subject to file 2019-11-21 0

    LU HONGBO

    • Director
    No longer subject to file 2019-11-21 0

    KLIMAN GILBERT H

    • Director
    • 10% Owner
    0 2019-06-14 0

    BURNS THOMAS WILLIAM

    • Director
    0 2019-06-14 0

    ORBIMED ADVISORS LLC

    ORBIMED ROF II LLC

    ORBIMED CAPITAL GP VI LLC

    • 10% Owner
    4,240,128 2019-02-19 0

    INTERWEST PARTNERS X LP

    ORONSKY ARNOLD L

    DESAI KEVAL

    NASR KHALED

    INTERWEST MANAGEMENT PARTNERS X, LLC

    • 10% Owner
    2,742,239 2019-02-19 0

    HEALTHQUEST PARTNERS II, L.P.

    HEALTHQUEST VENTURE MANAGEMENT II, L.L.C.

    • 10% Owner
    109,534 2019-02-13 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments